Observational, retrospective, prospective, pharmacological, single-centre, non-profit study. The aim is to evaluate, in newborns diagnosed with Congenital Hypothyroidism, the medium- and long-term efficacy and safety of the new formulation of levothyroxine in oral solution, compared to the liquid drop formulation and the tablet formulation. The study will involve male and female patients referred to the Neonatal Screening Centre at the Centre for Endocrine-Metabolic Diseases of the Paediatrics Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico di S. Orsola, Italy, who tested positive for Congenital Hypothyroidism.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Mean and median values of TSH
Timeframe: at 7-15 days, at 1-3-6-12 months and thereafter annually until 3 years after the start of therapy
Mean and median values of FT4
Timeframe: at 7-15 days, at 1-3-6-12 months and thereafter annually until 3 years after the start of therapy
Neuromotor-Neurocognitive development
Timeframe: at 1-3 years of age
Proportion of patients with adverse effects
Timeframe: at 7-15 days, at 1-3-6-12 months and thereafter annually until 3 years after the start of therapy